alexa Personalized Medicine: New Perspectives in Cancer Treatments
ISSN: 2153-0769
Metabolomics:Open Access

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
  • Conference Proceeding   
  • Metabolomics 2013, Vol 3(2): 121
  • DOI: 10.4172/2153-0769.1000121

Personalized Medicine: New Perspectives in Cancer Treatments

Meral Güzey1,2*
1University of Maryland University College-Europe, Heidelberg, Germany
2Harvard Medical School, Boston, MA, USA
*Corresponding Author: Meral Güzey, Department of Math and Life Sciences, Main campus of University Maryland University College (UMUC), USA, Email: [email protected]

Received Date: Jun 04, 2013 / Accepted Date: Aug 07, 2013 / Published Date: Aug 13, 2013

Prostate cancer is the most common non-cutaneous cancer in men [1,2]. PSA as a prostate cancer biomarker has served many years for the initial screening for prostate cancer. Later, there have been sincere efforts to complement this diagnostic test due to its misleading increased level for the indication of other diagnosis rather than PCa, such as BPH or inflammation [3-5]. We propose using particle swarm optimization heuristic technique, and a novel occurrence listing technique, to revise existing, available and possibly a novel biomarker. We aim to keep lists of the sequence elements, which offers criteria’s to evaluate randomly generated population of sequences to evaluate the solutions [6].

Our previous studies on VDR and apoptotic gene interactions highlighted the importance of VDR for prostate cancer field [7-10]. This brought novel perspective to the personal genomic research in cancer by considering combinational studies with natural compounds for novel therapies. My observation was differences in patient portfolio needed careful examination before application of the regimens. The importance of Vitamin D to the prostate cancer is impossible to ignore since ample amount of VDR is detected in prostate tissue [11-13].

Later, we showed that cDNA microarray data from human primary prostate cell lines provided important information on potential prostate cancer biomarkers. Our major challenge was to provide best normal control for our experiments [8]. This made me to realize the application differences between different geographical parts of the world. My question was: What might be the difference between “African American, and African men, or a male patient from Northern Europe to Middle Eastern” countries. The relationship between Vitamin D status and prostate cancer were in stronger differences between “Caucasians, Scandinavians and African-Americans”. There are also compelling evidence that inadequate Vitamin D exposures are associated with an increase in cancer risk and/or tumor progression [14]. The amount needed to curtail cancer remains elusive and therefore serves as a stimulus for continued investigations [15]. My observation was that each prostate cancer patient has his own individual demand for vitamin D3. Further, this problem can also exist for any other natural compounds and/ or drugs.

Presently, despite its controversy tPSA seems like the only marker routinely used in clinics. Each new assay needs to be standardized, without increasing costs unreasonably. Combination of both blood based biomarkers such as PSA(fPSA, tPSA, ProPSA, Human Kallikrein Panel/hK2, uPA, and urine based biomarkers such as, Pca3, Tmprss2- ERG, urinary DNA markers, can possibly overcome the lack of specificity of PSA test [1]. These suggested solutions are still using one gene–one test approach to molecular diagnostics. Our hope is that “sequence everything” approach can be done in a cost effective clinical cancer genomics [16]. It has been shown that sequencing not only the whole genome, but also the whole exome (the coding regions of the genome) and the whole transcriptome (the transcribed RNAs) of individual tumors in an effort to identify all potentially important anomalies including prostate cancer [17].

My report emerges that personal genetic information is the major clue to solve not only dose application in clinics but also any diagnostic applications. My wish is our landmark idea, which we have created by the interaction of software engineering and cancer genetics [18-20] can approach to massive patient groups with lower cost.


Dr. Meral Guzey acknowledges her sincere thanks to the Department of General Medicine, NIH, Bethesda, Maryland, USA (Research Supplements to Promote Re-Entry into Biomedical and Behavioral Research Careers (PA-08-191) in the years of 2009 and 2010 [20].


Citation: Güzey M (2013) Personalized Medicine: New Perspectives in Cancer Treatments. Metabolomics 3: 121. Doi: 10.4172/2153-0769.1000121

Copyright: © 2013 Güzey M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Leave Your Message 24x7